Table 2.

Lifetime Cost-effectiveness of Sofosbuvir/Ledipasvir-Based Therapies to Treat Hepatitis C in Comparison with the Old Standard of Care in 120 Patient Profiles

	QALY: oSOC	QALY: SOF-based	Cost: oSOC ($)	Cost: SOF-based ($)	ICER ($/QALY)	pCE at $50Kb	pCE at $100Kc
Treatment-Naive Patients
Genotype 1a
Non-cirrhoticb	10.605	11.056	54 052	68 228	31 452	0.77	0.99
Cirrhotic	8.279	9.447	85 170	96 498	9703	0.88	0.95
Genotype 2
Non-cirrhotic	10.669	11.041	22 736	78 230	149 463	0.02	0.23
Cirrhotic	8.378	9.161	46 336	95 208	62 428	0.36	0.74
Genotype 3
Non-cirrhotic	10.559	11.015	25 134	154 649	284 327	<0.01	0.01
Cirrhotic	8.119	9.354	50 235	167 634	95 083	0.10	0.43
Genotype 4
Non-cirrhotic	10.404	11.065	41 742	95 798	81 802	0.09	0.51
Cirrhotic	7.810	9.204	69 357	112 553	30 986	0.62	0.85
Genotypes 1–4
Non-cirrhotic	10.608	11.051	48 023	75 276	61 517	0.34	0.88
Cirrhotic	8.277	9.401	77 747	100 989	20 673	0.79	0.92
All treatment-naïve	10.035	10.646	55 326	81 593	43 034	0.45	0.89
Treatment-Experienced Patients
Genotype 1a
Non-cirrhotic	10.668	11.035	71 605	84 744	35 853	0.72	0.97
Cirrhotic	8.500	9.508	98 456	178 295	79 238	0.18	0.55
Genotype 2
Non-cirrhotic	10.648	11.048	26 650	78 161	128 770	0.01	0.20
Cirrhotic	8.380	8.580	48 868	105 046	281 317	0.08	0.08
Genotype 3
Non-cirrhotic	10.603	10.917	27 555	156 443	410 548	<0.01	<0.01
Cirrhotic	8.285	8.624	50 300	180 083	382 819	0.03	0.03
Genotype 4
Non-cirrhotic	10.215	10.732	45 496	87 245	80 793	0.09	0.56
Cirrhotic	7.796	8.790	69 938	104 102	34 349	0.61	0.85
Genotypes 1–4
Non-cirrhotic	10.657	11.026	62 699	88 433	69 707	0.25	0.76
Cirrhotic	8.463	9.324	88 662	168 069	92 302	0.12	0.45
All treatment-experienced	10.118	10.608	69 078	107 999	79 457	0.22	0.69
Treatment-Naive and Experienced Patients
All patientsd	10.067	10.631	60 686	91 886	55 378	0.35	0.83

Abbreviations: QALY, quality-adjusted life years; SOF, sofosbuvir; oSOC, old standard of care; LDV, ledipasvir; ICER, incremental cost-effectiveness ratio; pCE, probability of cost-effectiveness.

^aTreatment for genotype 1 patients was based on a combination of sofosbuvir and ledipasvir

^bNon-cirrhotic patients are defined as those having fibrosis scores F0–F3, and cirrhotic patients are defined as those having a fibrosis score F4

^bProbability of cost-effectiveness at a $50 000 willingness-to-pay threshold using probabilistic sensitivity analysis

^cProbability of cost-effectiveness at a $100 000 willingness-to-pay threshold using probabilistic sensitivity analysis

^dOverall results were estimated using the weighted average by representative proportion of the HCV population in the United States.